Recent investigations have focused on the convergence of glucagon-like peptide-1|GIP|glucagon receptor activator therapies and dopamine neurotransmission. While GCGR agonists are commonly employed for addressing type 2 diabetes, their potential impacts on reinforcement circuits, specifically mediated by dopamine networks, are receiving considera… Read More